Safety Study of a Shorter (Hypofractionated) Radiotherapy for the Prostate Bed With or Without the Pelvic Lymph Nodes

Inclusion Criteria: * resected prostate carcinoma with histological grading (Gleason Score) * status post prostatectomy for a pT3 carcinoma and/or R1/2 resection or PSA recurrence after prostatectomy (2 consecutive PSA rises) * PSA recurrence ≥ 1 ng/ml: CT/PET/MRI imaging excluding pathological lymph nodes * Karnofksy performance score ≥ 70 % * age 18 - 80 years * only arm 2: antihormonal therapy for 2 months prior to radiotherapy and continuation of hormonal suppression after radiotherapy recommended * written informed consent Exclusion Criteria: * patient's refusal * patient's inabillity to give informed consent * stage IV (distant metastases) * lymph node involvement outside the pelvis * severe wound complications after laparatomy * only arm 2: severe lymphoedema of the legs, elephantiasis, postthrombotic syndrome * decompensated pulmonary, cardiovascular, metabolic, hematopoetic, coagulatory or renal comorbidities * known other malignant disease with distant metastases * prior pelvic irradiation * participation in another clinical trial that might compromise the results of the PRIAMOS trial or the other trial